Oculis Holding AG - Ordinary shares

OCS54

$11.95arrow_drop_down0.16%-$0.02

OCS54

$11.95

arrow_drop_down0.16%-$0.02

Performance History

Key Stats
Open	$12.05
Prev. Close	$11.94
EPS	-1.64
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

PE Ratio	-

	LOW	HIGH
Day Range	11.90	12.05
52 Week Range	9.05	14.46

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-1.64

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Oculis Holding AG - Ordinary shares (OCS)

Oculis Holding AG is a company that specializes in the development and commercialization of innovative ophthalmic therapies. The company's main focus is on developing novel treatments for eye diseases, including glaucoma and diabetic retinopathy. Oculis Holding AG is headquartered in Switzerland and has a strong presence in Europe and the United States. The company's stock, OCS, is listed on the stock exchange and is available for trading to investors. OCS stock price history shows the historical performance of the stock over time, allowing investors to track its value and fluctuations in the market.

Oculis Holding AG's stock, OCS, can be quoted on various platforms, providing investors with up-to-date information about its current market value. OCS stock news covers the latest developments and news related to the company, including clinical trials, partnerships, and regulatory approvals. Investors can stay informed about the company's progress and make well-informed investment decisions based on the latest news. OCS stock analysis provides a detailed assessment of the stock's performance, including technical indicators, financial ratios, and market trends. This can help investors evaluate the stock's potential and make informed investment decisions.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. Riad Sherif M.B.A., M.D.
Headquarters: Zug
Employees: 28
Exchange: NASDAQ

add Oculis Holding AG - Ordinary shares to watchlist

Keep an eye on Oculis Holding AG - Ordinary shares

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Oculis Holding AG - Ordinary shares's (OCS) price per share?

The current price per share for Oculis Holding AG - Ordinary shares (OCS) is $11.95. The stock has seen a price change of -$0.02 recently, indicating a -0.17% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Oculis Holding AG - Ordinary shares (OCS)?

For Oculis Holding AG - Ordinary shares (OCS), the 52-week high is $14.46, which is 21.05% from the current price. The 52-week low is $9.05, the current price is 32.04% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Oculis Holding AG - Ordinary shares (OCS) a growth stock?

Oculis Holding AG - Ordinary shares (OCS) has shown an average price growth of 0.41% over the past three years. It has received a score of 73 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Oculis Holding AG - Ordinary shares as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Oculis Holding AG - Ordinary shares (OCS) stock price performance year to date (YTD)?

As of the latest data, Oculis Holding AG - Ordinary shares (OCS) has a year-to-date price change of 8.14%. Over the past month, the stock has experienced a price change of -0.42%. Over the last three months, the change has been 1.7%. Over the past six months, the figure is 0.84%.

help

Is Oculis Holding AG - Ordinary shares (OCS) a profitable company?

Oculis Holding AG - Ordinary shares (OCS) has a net income of -$88.7M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -9.18K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$45.85M. Furthermore, the EBITDA is -$74M.

help

What is the market capitalization of Oculis Holding AG - Ordinary shares (OCS)?

Oculis Holding AG - Ordinary shares (OCS) has a market capitalization of $498.44M. The average daily trading volume is 26.24K, indicating the stock's liquidity and investor engagement.

News

Oculis and EURETINA Announces the Ramin Tadayoni Award

CONTESTS/AWARDS

PHILANTHROPY

6/27/2024

Oculis and EURETINA Announces the Ramin Tadayoni Award

Alphabet To Rally Over 28%? Here Are 10 Top Analyst Forecasts For Tuesday

Alphabet To Rally Over 28%? Here Are 10 Top Analyst Forecasts For Tuesday

Oculis Announces Positive Topline Results of Phase 2b RELIEF Trial with Licaminlimab, Designed to Transform the Treatment Paradigm of Dry Eye Disease with a Precision Medicine Strategy

HEALTH

CLINICAL STUDY

CONFERENCE CALLS/ WEBCASTS

6/10/2024

Oculis Announces Positive Topline Results of Phase 2b RELIEF Trial with Licaminlimab, Designed to Transform the Treatment Paradigm of Dry Eye Disease with a Precision Medicine Strategy

REGULATORY INFORMATION

EUROPEAN REGULATORY NEWS

6/10/2024

Oculis Announces Positive Topline Results of Phase 2b RELIEF Trial with Licaminlimab, Designed to Transform the Treatment Paradigm of Dry Eye Disease with a Precision Medicine Strategy